SARS-CoV-2 Vaccine Safety in Adolescents with Inflammatory Rheumatic and Musculoskeletal Diseases and Adults with Juvenile Idiopathic Arthritis: Data from the EULAR COVAX Physician-Reported Registry - Sorbonne Université Access content directly
Journal Articles RMD Open : Rheumatic & Musculoskeletal Diseases Year : 2022

SARS-CoV-2 Vaccine Safety in Adolescents with Inflammatory Rheumatic and Musculoskeletal Diseases and Adults with Juvenile Idiopathic Arthritis: Data from the EULAR COVAX Physician-Reported Registry

Saskia Lawson-Tovey
  • Function : Author
Pedro M Machado
  • Function : Author
Anja Strangfeld
  • Function : Author
Elsa Mateus
  • Function : Author
Bernd Raffeiner
  • Function : Author
Inita Bulina
  • Function : Author
Daniel Clemente
  • Function : Author
Julija Zepa
  • Function : Author
Ana M. Rodrigues
  • Function : Author
Kimme L Hyrich
  • Function : Author

Abstract

Background There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs. Objectives To describe the safety of SARS-COV-2 vaccination in adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis (JIA). Methods We described patient characteristics, flares and adverse events (AEs) in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 or above with JIA submitted to the European Alliance of Associations for Rheumatology COVAX registry. Results A total of 110 cases were reported to the registry. Thirty-six adolescent cases were reported from four countries, most with JIA (42%). Over half (56%) reported early reactogenic-like AEs. One mild polyarthralgia flare and one serious AE of special interest (malaise) were reported. No CYP reported SARS-CoV-2 infection postvaccination. Seventy-four adult JIA cases were reported from 11 countries. Almost two-thirds (62%) reported early reactogenic-like AEs and two flares were reported (mild polyarthralgia and moderate uveitis). No serious AEs of special interest were reported among adults with JIA. Three female patients aged 20\textendash 30\,years were diagnosed with SARS-CoV-2 postvaccination; all fully recovered. Conclusions This is an important contribution to research on SARS-CoV-2 vaccine safety in adolescents with RMDs and adults with JIA. It is important to note the low frequency of disease flares, serious AEs and SARS-CoV-2 reinfection seen in both populations, although the dataset is limited by its size.
Fichier principal
Vignette du fichier
e002322.full.pdf (463.8 Ko) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-03894189 , version 1 (30-04-2024)

Licence

Identifiers

Cite

Saskia Lawson-Tovey, Pedro M Machado, Anja Strangfeld, Elsa Mateus, Laure Gossec, et al.. SARS-CoV-2 Vaccine Safety in Adolescents with Inflammatory Rheumatic and Musculoskeletal Diseases and Adults with Juvenile Idiopathic Arthritis: Data from the EULAR COVAX Physician-Reported Registry. RMD Open : Rheumatic & Musculoskeletal Diseases, 2022, 8 (2), pp.e002322. ⟨10.1136/rmdopen-2022-002322⟩. ⟨hal-03894189⟩
13 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More